{
    "organizations": [],
    "uuid": "5431e1e9b8e1fd6a4364c8d2a5695997936d7b7f",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/02/27/globe-newswire-coherus-biosciences-to-report-fourth-quarter-and-full-year-2017-financial-results-on-march-8th.html",
    "ord_in_thread": 0,
    "title": "Coherus BioSciences to Report Fourth Quarter and Full Year 2017 Financial Results on March 8th",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "REDWOOD CITY, Calif., Feb. 27, 2018 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Nasdaq:CHRS), today announced that its fourth quarter and full year 2017 financial results will be released after market close on Thursday, March 8, 2018. At 4:30 p.m. Eastern Time, Coherus’ management will host a conference call to discuss the financial results and provide a general business update.\nAfter releasing fourth quarter and full year 2017 financial results, we will post them on the Coherus BioSciences website at http://investors.coherus.com .\nConference Call Information\nWhen: Thursday, March 8, 2018 at 4:30 p.m. ET\nDial-in: (844) 452-6826 (toll free) or (765) 507-2587 (International)\nConference ID: 7098068\nWebcast: http://investors.coherus.com\nPlease join the conference call at least 10 minutes early to register. The webcast will be archived on the Coherus website.\nAbout Coherus BioSciences, Inc.\nCoherus is a leading pure-play, global biosimilar company that develops and commercializes high-quality therapeutics for major regulated markets. Biosimilars are intended for use in place of existing, branded biologics to treat a range of chronic and often life-threatening diseases, with the potential to reduce costs and expand patient access. Composed of a team of proven industry veterans with world-class expertise in process science, analytical characterization, protein production, sales & marketing and clinical-regulatory development, Coherus is positioned as a leader in the global biosimilar marketplace. Coherus is advancing three late-stage clinical products towards commercialization, CHS-1701 (pegfilgrastim biosimilar), CHS-1420 (adalimumab biosimilar) and CHS-0214 (etanercept biosimilar), as well as developing a robust pipeline of future products in four therapeutic areas, oncology, immunology (anti-TNF), ophthalmology including CHS-3351 (ranibizumab biosimilar) and CHS-2020 (aflibercept biosimilar), and CHS-131, a small molecule for multiple sclerosis. For additional information, please visit www.coherus.com .\nCONTACT:\nPatrick O’Brien\nSenior Vice President, Investor Relations\nCoherus BioSciences, Inc.\npobrien@coherus.com\n+1 (650) 649-3527\nSource:Coherus BioSciences, Inc.",
    "published": "2018-02-27T17:00:00.000+02:00",
    "crawled": "2018-02-27T16:37:44.086+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "redwood",
        "city",
        "globe",
        "newswire",
        "coherus",
        "bioscience",
        "nasdaq",
        "chrs",
        "today",
        "announced",
        "fourth",
        "quarter",
        "full",
        "year",
        "financial",
        "result",
        "released",
        "market",
        "close",
        "thursday",
        "march",
        "eastern",
        "time",
        "coherus",
        "management",
        "host",
        "conference",
        "call",
        "discus",
        "financial",
        "result",
        "provide",
        "general",
        "business",
        "update",
        "releasing",
        "fourth",
        "quarter",
        "full",
        "year",
        "financial",
        "result",
        "post",
        "coherus",
        "bioscience",
        "website",
        "http",
        "conference",
        "call",
        "information",
        "thursday",
        "march",
        "et",
        "toll",
        "free",
        "international",
        "conference",
        "id",
        "webcast",
        "http",
        "please",
        "join",
        "conference",
        "call",
        "least",
        "minute",
        "early",
        "register",
        "webcast",
        "archived",
        "coherus",
        "website",
        "coherus",
        "bioscience",
        "coherus",
        "leading",
        "global",
        "biosimilar",
        "company",
        "develops",
        "commercializes",
        "therapeutic",
        "major",
        "regulated",
        "market",
        "biosimilars",
        "intended",
        "use",
        "place",
        "existing",
        "branded",
        "biologics",
        "treat",
        "range",
        "chronic",
        "often",
        "disease",
        "potential",
        "reduce",
        "cost",
        "expand",
        "patient",
        "access",
        "composed",
        "team",
        "proven",
        "industry",
        "veteran",
        "expertise",
        "process",
        "science",
        "analytical",
        "characterization",
        "protein",
        "production",
        "sale",
        "marketing",
        "development",
        "coherus",
        "positioned",
        "leader",
        "global",
        "biosimilar",
        "marketplace",
        "coherus",
        "advancing",
        "three",
        "clinical",
        "product",
        "towards",
        "commercialization",
        "pegfilgrastim",
        "biosimilar",
        "adalimumab",
        "biosimilar",
        "etanercept",
        "biosimilar",
        "well",
        "developing",
        "robust",
        "pipeline",
        "future",
        "product",
        "four",
        "therapeutic",
        "area",
        "oncology",
        "immunology",
        "ophthalmology",
        "including",
        "ranibizumab",
        "biosimilar",
        "aflibercept",
        "biosimilar",
        "small",
        "molecule",
        "multiple",
        "sclerosis",
        "additional",
        "information",
        "please",
        "visit",
        "contact",
        "patrick",
        "brien",
        "senior",
        "vice",
        "president",
        "investor",
        "relation",
        "coherus",
        "bioscience",
        "pobrien",
        "source",
        "coherus",
        "bioscience",
        "inc"
    ]
}